REGENXBIO Inc.
Symbol: RGNX (NASDAQ)
9.39
▼ (-1.02%) -0.097
Company Description:
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Key Stats
- Today's Open: $9.47
- Today's High: $9.525
- Today's Low: $9.254
- Today's Volume: 58.70K
- Yesterday Close: $9.49
- Yesterday High: $9.82
- Yesterday Low: $9.145
- Yesterday Volume: 371.09K
- Last Min Volume: 56
- Last Min High: $9.393
- Last Min Low: $9.382
- Last Min VWAP: $9.382
Company Profile
- Name: REGENXBIO Inc.
- Website: https://www.regenxbio.com
- Listed Date: 2015-09-17
- Location: ROCKVILLE, MD
- Market Status: Active
- CIK Number: 0001590877
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $483.42M
- Round Lot: 100
- Outstanding Shares: 50.51M
- Asset Type: CS
RECENT FILINGS FOR RGNX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-10 | 144 | View |
| 2025-09-03 | 4 | View |
| 2025-09-03 | 4 | View |
| 2025-08-18 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-08-04 | 4 | View |
| 2025-07-15 | SCHEDULE 13G | View |
| 2025-07-03 | 4 | View |
| 2025-06-25 | EFFECT | View |
| 2025-06-25 | 424B3 | View |
| 2025-06-23 | CORRESP | View |
| 2025-06-20 | UPLOAD | View |
| 2025-06-13 | S-3 | View |
| 2025-06-13 | S-8 | View |
| 2025-06-03 | 4 | View |
| 2025-06-03 | 4 | View |
| 2025-06-03 | 4 | View |
| 2025-06-03 | 4 | View |
Latest News on RGNX